Neuropathology-defined Alzheimer's disease transcriptomic programs converge in blood at mild cognitive impairment
Journal of Alzheimer’s Disease · 19.11.2026
DOI: 10.1177/13872877261507716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 19.11.2026. Verfasst von Songnian Lu und 5 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities.
Themen: Demenz
Abstract (Originalsprache)
Background
Blood transcriptomic studies in Alzheimer's disease (AD) often train signatures directly in blood, making it unclear whether signals reflect brain disease programs, blood-cell composition, or cohort structure.
Objective
To test how neuropathology-defined AD transcriptional programs appear in blood, whether distinct brain programs show a shared peripheral pattern, and whether that pattern is most evident during mild cognitive impairment (MCI).
Methods
Three directional gene sets were derived before blood analysis from postmortem brain RNA-seq (GSE278723) to represent amyloid-associated, neurodegeneration-related, and core AD changes. These brain-defined programs were projected into five whole-blood cohorts (1975 participants) using directional single-sample Gene Set Enrichment Analysis and assessed for stage-specific patterns, comparison with size-matched random sets, sensitivity to estimated cell composition, dimensionality, held-out classification, and association with Alzheimer's Disease Neuroimaging Initiative (ADNI) genetic and fluid biomarkers.
Results
Brain-derived AD programs were detected across blood cohorts and showed a shared rather than separable pattern. Scores were highest at MCI, exceeded size-matched random baselines, and were not primarily explained by estimated blood-cell proportions. In GSE63060, P1/P2/P5 scores formed a dominant axis, with PC1 explaining 92.2% of directional half-score variance. A held-out classifier achieved AUC = 0.822, and ADNI analyses showed information beyond APOE ε4 and improved discrimination when blood scores were combined with cerebrospinal fluid pTau181/Aβ 42 .
Conclusions
Neuropathology-defined AD transcriptomic programs form a shared peripheral axis that is most evident at MCI. This brain-anchored signal adds a systemic transcriptional dimension to genetic and fluid biomarkers and provides a biological framework for studying early AD-related disease in blood.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Lu, S., Mao, H., Rui, X., Hou, X., Qian, M., & Wu, X. (2026). Neuropathology-defined Alzheimer's disease transcriptomic programs converge in blood at mild cognitive impairment. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261507716
Vancouver
Lu S, Mao H, Rui X, Hou X, Qian M, Wu X. Neuropathology-defined Alzheimer's disease transcriptomic programs converge in blood at mild cognitive impairment. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261507716
BibTeX
@article{Lu2026,
author = {Lu, Songnian and Mao, Hongyuan and Rui, Xiaoya and Hou, Xiaohui and Qian, Mengcen and Wu, Xingjiao},
title = {Neuropathology-defined Alzheimer's disease transcriptomic programs converge in blood at mild cognitive impairment},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261507716}
}
EUVIMED